# Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

> **NCT05626322** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 6 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Maplirpacept
- **DRUG:** Tafasitamab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT05626322
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-04
- **Primary completion:** 2024-08-12
- **Final completion:** 2025-05-01
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The trial terminated due to the inability to recruit the planned number of subjects. The decision was not based on any safety and/or efficacy concerns
- **Last updated:** 2025-09-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05626322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05626322, "Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05626322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*